Q&A Project Optimus: What you need to know

The study designs and dose-finding strategies that have dominated decades of oncology drug development are becoming obsolete as the FDA’s Project Optimus takes full effect. We rounded up our regulatory experts and asked them to share their perspectives on 28 of the top questions from sponsors.


Open PDF

Return to Insights Center

Related Insights

Article

Five strategies for meeting the requirements of Project Optimus and improving the chances of approval

Nov 10, 2022

Article

New endpoints for early-stage cancer are gaining regulatory traction

Jan 28, 2022

Podcast

RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry

Jun 16, 2022

Blog

Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021

Video

Creating EU-CTR compliant and patient-friendly lay language summaries (LLS)

Jan 26, 2022

Video

On-demand webinar: An expert guide to EU-CTR

Mar 10, 2022

Article

New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle

May 10, 2022

Blog

Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions

May 16, 2022

Blog

Parexel names first Patient Ambassador

Jun 17, 2022

Video

Part 3: Risk-based Quality Management Video (RBQM) Series

Nov 11, 2021

Article

8 things you need to know about eCTDs in China

Jul 1, 2022

Blog

Preparing for the New Era of Hybrid Regulatory Inspections

Jul 11, 2022